MD-18 / Radella Pharmaceuticals - LARVOL DELTA

Subcutaneously Administered MD-18 for the Treatment of Obesity and Diabetes (clinicaltrials.gov) - P1 | N=54 | Recruiting | Sponsor: Cohen Global, Ltd. | Trial completion date: Dec 2025 ➔ Mar 2026 | Trial primary completion date: Nov 2025 ➔ Feb 2026

Trial completion date • Trial primary completion date • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

Radella Pharmaceuticals Announces New Obesity Trial Data Showing Statistically Significant Weight Loss and Broader Cardiometabolic Benefits (PRNewswire) - P1b | N=54 | NCT06739707 | Sponsor: Cohen Global, Ltd. | "The double‑blind, placebo‑controlled...MAD Phase 1b trial enrolled healthy volunteers [n=36]....Significant weight loss of up to 2.7% in otherwise healthy volunteers in 28 days of treatment. These results were seen in primarily non-obese subjects and were accompanied by a 2.2% decrease in waist circumference with weekly administration....In healthy subjects with elevated LDL cholesterol levels, MD-18 demonstrated a statistically significant decrease in LDL cholesterol vs. placebo. Further, MD-18 demonstrated a statistically significant decrease in alanine aminotransferase (ALT) levels vs. placebo, suggesting the potential to reduce liver fat content....Radella will initiate two additional cohorts in the intent-to-treat population, including obese patients without type 2 diabetes and overweight and obese patients with type 2 diabetes....The company expects to report topline data from these cohorts in Q1 2026."

P1 data • Trial status • Obesity

Subcutaneously Administered MD-18 for the Treatment of Obesity and Diabetes (clinicaltrials.gov) - P1 | N=54 | Recruiting | Sponsor: Cohen Global, Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity